Protalix BioTherapeutics (PLX) Long-Term Investments (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Long-Term Investments of $589000.0 for Q1 2026, up 28.32% year-over-year from $459000.0 in Q1 2025, and up 1.9% quarter-over-quarter from $578000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Long-Term Investments (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Long-Term Investments history runs 17 years deep, the most recent figure standing at $589000.0 for Q1 2026.
- In Q1 2026, Long-Term Investments rose 28.32% year-over-year to $589000.0; the TTM figure through Mar 2026 stood at $589000.0 (up 28.32% YoY), while the FY2025 annual figure was $578000.0, up 25.11% from the prior year.
- Long-Term Investments for Q1 2026 stood at $589000.0, up from $578000.0 in the prior quarter.
- The five-year high for Long-Term Investments was $2.1 million in Q1 2022, with the low at $459000.0 in Q1 2025.
- The 5-year median for Long-Term Investments is $578000.0 (2025), against an average of $896000.0.
- The sharpest annual moves came in 2023 and 2026: Long-Term Investments sank 58.33% in 2023, then gained 28.32% in 2026.
- Protalix BioTherapeutics' Long-Term Investments stood at $1.3 million in 2022, then plunged by 58.33% to $528000.0 in 2023, then retreated by 12.5% to $462000.0 in 2024, then climbed by 25.11% to $578000.0 in 2025, then gained by 1.9% to $589000.0 in 2026.
- Business Quant data shows PLX's Long-Term Investments at $589000.0 in Q1 2026, $578000.0 in Q4 2025, and $549000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 589,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Sep 30, 2025 | 549,000.00 |
| Jun 30, 2025 | 520,000.00 |
| Mar 31, 2025 | 459,000.00 |
| Dec 31, 2024 | 462,000.00 |
| Sep 30, 2024 | 561,000.00 |
| Jun 30, 2024 | 535,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 528,000.00 |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 2.05 Mn |
| Dec 31, 2021 | 2.08 Mn |
| Sep 30, 2021 | 1.95 Mn |
| Jun 30, 2021 | 1.88 Mn |